Targeting Cannabinoid Receptors in HER2 positive tumours.

HER2+乳腺癌的特征在于HER2受体酪氨酸激酶的过表达。这种侵袭性亚型约占乳腺癌病例的20%。然而，尽管靶向治疗取得了成功，但耐药性仍然是一个问题。对于转移性疾病患者尤其如此。大麻素2受体（CB2R）的表达已被证明是由HER2表达诱导，并提出了一个有吸引力的新的药物靶点。这项工作旨在验证HER2和CB2靶向治疗的药理学特性和表型影响。使用具有诱导型CB2R表达的2D和3D体外模型，将进一步剖析CB2R调节后肿瘤的代谢和侵袭特征。这是一个终点，以测试专有的合成大麻素，旨在调节CB2R的促肿瘤作用。

HER2+ breast cancer is characterised by the overexpression of the HER2 receptor tyrosine kinase. This aggressive subtype accounts for around 20% of breast cancer cases. However, despite success with targeted therapies resistance is still a concern. This is especially the case for patients with metastatic disease. Cannabinoid 2 receptor (CB2R) expression has been shown to be induced by HER2 expression and presents an appealing novel druggable target. This work aims to characterise the pharmacological properties and phenotypic impacts of HER2- and CB2-targeted therapies. Using 2D and 3D in vitro models with inducible CB2R expression, the metabolic and invasive characteristics of tumours after CB2R modulation will be dissected further. This is with an endpoint to test proprietary synthetic cannabinoids that aim to modulate the pro-tumorigenic actions of CB2Rs.